CLPT Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2016βFY2025
ClearPoint Neuro, Inc. had $37.0M of revenue in fiscal 2025, up 17.8% on the year before. Over five years, revenue changed +23.6% a year on average.
Last close Β· Oct 23, 2026
$9.14
1.2%Hi! I read ClearPoint Neuro, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+17.8%
Yes. Sales grew 17.8% last year.
Does it make a profit?
β69.1%
No. It lost money last year.
Does profit turn into cash?
β66.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days ClearPoint Neuro, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
October 28, 2026
Wednesday Β· in 2 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 3, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 13, 2026 | Q1 '26 | After the market closes | 8-K β |
| Jan 12, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 6, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 12, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 13, 2025 | Q1 '25 | After the market closes | 8-K β |
| Feb 26, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 7, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· ClearPoint Neuro, Inc. had $37.0M of revenue in fiscal 2025, up 17.8% on the year before. Over five years, revenue changed +23.6% a year on average. Its operating margin was β65.4%, down 2.5Β pts: of every 100 in sales, about β65 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· ClearPoint Neuro, Inc. lost $25.5M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$24.4M in fiscal 2025, β66.1% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· ClearPoint Neuro, Inc. owes $3.2M more than it holds in cash.
Cash, debt and the ratios that show how comfortably ClearPoint Neuro, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $54.1M | $37.5M | $23.1M | $20.1M | $45.9M |
| Debt incl. finance leases | $9.8M | $9.9M | $9.9M | β | $49.1M |
| Debt / equity | 0.2x | 0.3x | 0.5x | β | 1.8x |
| Interest coverage | β13.7x | β201.6x | β | β38.1x | β10.1x |
| Current ratio | 13.0x | 7.5x | 4.9x | 3.2x | 5.9x |
| Quick ratio | 12.0x | 6.2x | 3.8x | 2.6x | 5.1x |
| Total assets | $65.6M | $55.5M | $42.7M | $39.2M | $97.7M |
| Total liabilities | $16.8M | $18.6M | $21.5M | $13.8M | $69.7M |
| Shareholders' equity | $48.8M | $36.9M | $21.2M | $25.4M | $28.0M |
| Net debt (β = net cash) | β$44.3M | β$27.6M | β$13.2M | β | $3.2M |
KIRA Β· Its return on capital was β61.2%: every 100 invested in the business earned about β61 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· ClearPoint Neuro, Inc. passes 4 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 9 | 4 / 9 | 4 / 9 | 3 / 9 | 4 / 9 | 2 / 9 | 2 / 9 | 4 / 8 | 4 / 8 |
| Accruals ratio | β30.4% | β11.0% | β14.1% | β27.2% | 4.9% | β3.6% | β0.4% | β17.1% | β24.3% | β2.4% |
| Altman Z'' | β45.53 | β22.07 | β44.72 | β29.14 | β9.58 | 0.74 | β3.48 | β11.26 | β13.52 | β4.93 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $5.7M | $7.4M | $7.4M | $11.2M | $12.8M | $16.3M | $20.6M | $24.0M | $31.4M | $37.0M |
| Net interest income | β | β | β | β | β | β | β$0.1M | $0.4M | $0.9M | β |
| Gross profit | $3.1M | $4.5M | $4.9M | $7.3M | $9.1M | $11.1M | $13.5M | $13.6M | $19.1M | $22.7M |
| Research and development | $2.6M | $2.8M | $2.3M | $2.8M | $4.7M | $9.3M | $10.9M | $11.7M | $12.4M | $13.9M |
| Operating income | β$7.5M | β$6.3M | β$5.2M | β$4.6M | β$6.2M | β$13.4M | β$16.3M | β$22.4M | β$19.7M | β$24.2M |
| Interest expense | $1.1M | $0.9M | $1.0M | $1.0M | $1.4M | $1.0M | $0.1M | β | $0.5M | $2.4M |
| Pretax income | β | β | β | β | β | β | β | β | β$18.9M | β$25.5M |
| Income tax | β | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M |
| Net income | β$8.1M | β$7.2M | β$6.2M | β$5.5M | β$6.8M | β$14.4M | β$16.4M | β$22.1M | β$18.9M | β$25.5M |
| Diluted EPS | β$2.93 | β$0.93 | β$0.56 | β$0.42 | β$0.43 | β$0.69 | β$0.68 | β$0.90 | β$0.70 | β$0.90 |
| Diluted shares | 0.00B | 0.01B | 0.01B | 0.01B | 0.02B | 0.02B | 0.02B | 0.02B | 0.03B | 0.03B |
| Cash flow | ||||||||||
| Cash from operations | β$5.8M | β$6.0M | β$4.6M | β$2.9M | β$7.8M | β$12.7M | β$16.2M | β$13.7M | β$9.0M | β$23.9M |
| Capital expenditure | $0.1M | $0.0M | $0.1M | $0.0M | $0.0M | $0.2M | $0.3M | $0.7M | $0.3M | $0.5M |
| Free cash flow | β$5.9M | β$6.0M | β$4.7M | β$2.9M | β$7.8M | β$12.9M | β$16.4M | β$14.4M | β$9.2M | β$24.4M |
| Depreciation and amortization | $0.2M | $0.1M | $0.1M | $0.1M | $0.3M | $0.2M | $0.2M | $0.6M | $1.0M | $0.8M |
| Stock-based compensation | $1.2M | $1.2M | $1.2M | $0.8M | $1.1M | $2.1M | $4.1M | $6.1M | $6.9M | $8.2M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $3.3M | $9.3M | $3.1M | $5.7M | $20.1M | $54.1M | $37.5M | $23.1M | $20.1M | $45.9M |
| Total debt | $4.5M | $4.9M | $3.5M | $2.1M | $21.3M | $9.8M | $9.9M | $9.9M | β | $49.1M |
| Current assets | $6.1M | $12.7M | $6.7M | $10.4M | $25.5M | $61.9M | $51.2M | $36.2M | $33.4M | $63.6M |
| Current liabilities | $3.0M | $4.4M | $1.9M | $3.8M | $3.2M | $4.8M | $6.8M | $7.4M | $10.4M | $10.8M |
| Inventory | $1.8M | $2.3M | $2.1M | $3.2M | $3.2M | $4.9M | $9.3M | $7.9M | $6.9M | $8.4M |
| Property and equipment, net | $0.3M | $0.3M | $0.4M | $0.4M | $0.3M | $0.5M | $0.8M | $1.4M | $2.0M | $2.6M |
| Goodwill | β | β | β | β | β | β | β | β | $7.5M | $7.5M |
| Intangible assets | β | β | β | β | β | β | β | β | $0.0M | $13.9M |
| Total assets | $7.4M | $13.9M | $7.9M | $11.9M | $29.5M | $65.6M | $55.5M | $42.7M | $39.2M | $97.7M |
| Total liabilities | $8.2M | $8.1M | $6.3M | $7.3M | $27.1M | $16.8M | $18.6M | $21.5M | $13.8M | $69.7M |
| Preferred stock | β | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | β$0.8M | $5.8M | $1.5M | $4.6M | $2.4M | $48.8M | $36.9M | $21.2M | $25.4M | $28.0M |
| Margins | ||||||||||
| Gross margin | 54.0% | 60.7% | 66.9% | 64.9% | 71.1% | 68.2% | 65.8% | 56.8% | 60.9% | 61.4% |
| Operating margin | β130.2% | β85.9% | β71.4% | β41.0% | β48.5% | β82.1% | β79.5% | β93.7% | β62.9% | β65.4% |
| EBITDA margin | β127.5% | β84.3% | β69.9% | β39.7% | β45.9% | β81.1% | β78.3% | β91.1% | β59.7% | β63.2% |
| Net margin | β140.4% | β97.1% | β83.8% | β49.4% | β52.9% | β88.4% | β80.0% | β92.2% | β60.3% | β69.1% |
| FCF margin | β103.0% | β81.6% | β63.8% | β25.5% | β61.2% | β78.9% | β79.9% | β60.3% | β29.4% | β66.1% |
| Net interest share of revenue | β | β | β | β | β | β | β0.4% | 1.6% | 2.8% | β |
| Returns | ||||||||||
| Return on capital | β1,408.9% | β343.5% | β219.4% | β377.0% | β138.1% | β234.0% | β138.9% | β222.2% | β | β61.2% |
| Return on capital employed | β170.9% | β66.7% | β87.6% | β56.8% | β23.6% | β22.0% | β33.5% | β63.7% | β68.4% | β27.8% |
| Return on equity | β | β282.6% | β168.0% | β181.8% | β194.8% | β56.3% | β38.4% | β76.1% | β81.2% | β95.6% |
| Return on assets | β109.0% | β67.3% | β56.7% | β56.0% | β32.7% | β30.3% | β27.1% | β45.0% | β46.2% | β37.3% |
| Return on tangible equity | β | β123.0% | β408.2% | β120.8% | β285.3% | β29.5% | β44.6% | β104.3% | β105.6% | β385.5% |
| Growth | ||||||||||
| Revenue growth | β | 28.4% | β0.4% | 52.5% | 14.4% | 27.0% | 26.1% | 16.6% | 31.0% | 17.8% |
| Share count change | β | 180.9% | 41.2% | 20.4% | 20.5% | 30.8% | 16.6% | 1.8% | 9.8% | 4.8% |
| Financial health | ||||||||||
| Debt / equity | β | 0.8x | 2.3x | 0.5x | 9.0x | 0.2x | 0.3x | 0.5x | β | 1.8x |
| Interest coverage | β7.1x | β7.3x | β5.4x | β4.8x | β4.3x | β13.7x | β201.6x | β | β38.1x | β10.1x |
| Current ratio | 2.0x | 2.9x | 3.6x | 2.7x | 8.0x | 13.0x | 7.5x | 4.9x | 3.2x | 5.9x |
| Quick ratio | 1.4x | 2.4x | 2.4x | 1.9x | 6.9x | 12.0x | 6.2x | 3.8x | 2.6x | 5.1x |
| Capital allocation | ||||||||||
| Capex / revenue | 1.8% | 0.4% | 0.9% | 0.1% | 0.3% | 1.0% | 1.2% | 3.0% | 0.9% | 1.4% |
| Stock comp / revenue | 20.6% | 16.9% | 16.7% | 7.1% | 8.5% | 12.7% | 20.1% | 25.4% | 22.0% | 22.1% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 5.0 | 4.0 | 4.0 | 3.0 | 4.0 | 2.0 | 2.0 | 4.0 | 4.0 |
| Altman Z'' | β45.5 | β22.1 | β44.7 | β29.1 | β9.6 | 0.7 | β3.5 | β11.3 | β13.5 | β4.9 |
| Accruals ratio | β30.4% | β11.0% | β14.1% | β27.2% | 4.9% | β3.6% | β0.4% | β17.1% | β24.3% | β2.4% |
Source: SEC EDGAR XBRL filings (CIK 0001285550). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
